EGFR and lung carcinoma: EGFR is a well‐known driver gene in lung cancer, with a significant percentage of patients carrying mutations in this gene.[30, 31] The third‐generation EGFR‐TKI osimertinib is an effective solution for overcoming resistance triggered by the T790M mutation, a common occurrence following treatment with first‐ and second‐generation TKIs.